Cambrex Corporation (CBM) EPS Estimated At $1.11

January 22, 2018 - By Hazel Jackson

 Cambrex Corporation (CBM) EPS Estimated At $1.11
Investors sentiment increased to 1.58 in Q3 2017. Its up 0.59, from 0.99 in 2017Q2. It increased, as 18 investors sold Cambrex Corporation shares while 61 reduced holdings. 41 funds opened positions while 84 raised stakes. 31.63 million shares or 2.69% more from 30.80 million shares in 2017Q2 were reported.
California Employees Retirement has 0.01% invested in Cambrex Corporation (NYSE:CBM) for 77,566 shares. Eaton Vance Mgmt invested in 0.04% or 272,056 shares. Thrivent Financial For Lutherans has invested 0% in Cambrex Corporation (NYSE:CBM). Glenhill Advsr Ltd holds 399,667 shares. Cornerstone Incorporated reported 290 shares. State Teachers Retirement owns 94,680 shares for 0.01% of their portfolio. Invesco Ltd reported 642,775 shares. Grp One Trading L P has invested 0% in Cambrex Corporation (NYSE:CBM). Connor Clark And Lunn Mngmt invested 0.01% in Cambrex Corporation (NYSE:CBM). Rice Hall James & Associate Llc has invested 0.08% of its portfolio in Cambrex Corporation (NYSE:CBM). Fifth Third Bank & Trust holds 344 shares. First Lp holds 24,186 shares. Lpl Fincl Limited Company holds 0% or 5,267 shares in its portfolio. Employees Retirement Sys Of Ohio holds 78,619 shares or 0.02% of its portfolio. Eqis Mgmt Inc holds 0.23% or 75,777 shares in its portfolio.

Since August 1, 2017, it had 0 insider buys, and 3 sales for $1.57 million activity.

Analysts expect Cambrex Corporation (NYSE:CBM) to report $1.11 EPS on February, 2.They anticipate $0.07 EPS change or 5.93 % from last quarter’s $1.18 EPS. CBM’s profit would be $36.38 million giving it 12.68 P/E if the $1.11 EPS is correct. After having $0.55 EPS previously, Cambrex Corporation’s analysts see 101.82 % EPS growth. The stock increased 0.54% or $0.3 during the last trading session, reaching $56.3. About 304,025 shares traded. Cambrex Corporation (NYSE:CBM) has risen 11.15% since January 22, 2017 and is uptrending. It has underperformed by 5.55% the S&P500.

Cambrex Corporation (NYSE:CBM) Ratings Coverage

Among 6 analysts covering Cambrex Corp (NYSE:CBM), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cambrex Corp had 7 analyst reports since July 21, 2015 according to SRatingsIntel. Craig Hallum maintained Cambrex Corporation (NYSE:CBM) rating on Tuesday, October 31. Craig Hallum has “Buy” rating and $60.0 target. Singular Research maintained Cambrex Corporation (NYSE:CBM) rating on Thursday, February 11. Singular Research has “Buy” rating and $60 target. First Analysis maintained Cambrex Corporation (NYSE:CBM) on Tuesday, January 17 with “Overweight” rating. William Blair maintained the stock with “Buy” rating in Tuesday, January 16 report. The stock of Cambrex Corporation (NYSE:CBM) earned “Overweight” rating by First Analysis on Monday, November 7. Stephens initiated it with “Overweight” rating and $55 target in Tuesday, July 21 report.

Cambrex Corporation, a life sciences company, provides various services and products for the development and commercialization of new and generic therapeutics worldwide. The company has market cap of $1.85 billion. The company??s products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. It has a 18.85 P/E ratio. It serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics.

Another recent and important Cambrex Corporation (NYSE:CBM) news was published by which published an article titled: “Cambrex & AstraZeneca Hold Ceremony to Mark Long-Term Supply Agreement at …” on January 16, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: